The fatty acid amide hydrolase inhibitor, URB597, an endocannabinoid enhancing drug, reverses social withdrawal in the sub-chronic PCP rat model of schizophrenia, but reduces social interaction (SI) in controls. To identify the anatomical substrates associated with PCP-induced social withdrawal and the contrasting effects of URB597 on SI in PCP-versus saline-treated rats, we analyzed SI-induced c-Fos expression in 28 brain areas relevant to schizophrenia and/or social behavior following vehicle or URB597 administration. In saline-treated rats, SI was accompanied by changes in c-Fos expression in the infralimbic and orbitofrontal cortices, dorsomedial caudate putamen, ventrolateral nucleus of the septum, dorsolateral periaqueductal gray (dlPAG) and central amygdala. Except for the dlPAG, these changes were not observed in PCP-treated rats or in saline-treated rats receiving URB597. In the dorsomedial part of the bed nucleus of the stria terminalis (dmBNST), SI-induced c-Fos expression was observed only in PCP-treated rats. Interestingly, URB597 in PCP-treated rats restored a similar c-Fos expression pattern as observed in saline-treated rats: activation of the orbitofrontal cortex, inhibition of the central amygdala and suppression of activation of the dmBNST. These data suggest that orbitofrontal cortex, central amygdala and dmBNST play a critical role in the reversal of PCP-induced social withdrawal by URB597.
Introduction
Schizophrenia is a debilitating psychiatric disorder affecting 1% of world population (Tandon et al., 2008) . The associated cognitive (e.g. attention and memory deficits), positive (e.g. delusions and hallucinations), and negative symptoms (e.g. anhedonia and social withdrawal) significantly impair patients' personal and professional lives. In particular, negative symptoms often lead to homelessness and are thought to be the primary driver for suicide in schizophrenics (Balhara and Verma, 2012) . Antipsychotic pharmacotherapy has shown some success in alleviating positive Abbreviations: AEA, anandamide; BNST, bed nucleus of the stria terminalis; BLA, basolateral amygdala; CeA, central amygdala; CPu, caudate putamen; FAAH, fatty acid amide hydrolase; MDT, mediodorsal thalamus; PAG, periaqueductal gray; PCP, phencyclidine; ROI, region of interest; SI, social interaction; VLS, ventrolateral septum.
* symptoms; however, treatment options for negative and cognitive symptoms remain very limited. Consequently, there is an urgent need to decipher the underlying causes of these symptoms and develop new pharmacological strategies.
Human studies indicate that a dysfunction of the endocannabinoid system might play a role in the pathophysiology of this mental disorder. Postmortem studies in schizophrenic patients have shown altered expression levels of cannabinoid CB1 receptors in several brain areas, including the dorsolateral prefrontal cortex (Dean et al., 2001; Eggan et al., 2008; Uriguen et al., 2009; Eggan et al., 2010; Dalton et al., 2011) and cingulate cortex (Zavitsanou et al., 2004; Newell et al., 2006) . Abnormal endocannabinoid transmission has been also associated to negative symptoms. For example, in drug naïve schizophrenics, increased cerebrospinal fluid levels of the endocannabinoid anandamide (AEA) (Leweke et al., 1999; Giuffrida et al., 2004; Leweke et al., 2007; Koethe et al., 2009) were inversely correlated to the severity of negative symptoms (Giuffrida et al., 2004) , suggesting that increased AEA production may be beneficial in schizophrenia.
Using the sub-chronic phencyclidine (PCP) rat model of schizophrenia (Jentsch et al., 1997; Seillier and Giuffrida, 2009 ), we previously showed that PCP-induced social withdrawal, a http://dx.doi.org/10.1016/j.neures.2016.04.004 0168-0102/© 2016 Elsevier Ireland Ltd and Japan Neuroscience Society. All rights reserved.
